SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Ascent Therapeutics Achieves Preclinical in vivo Proof-of-Principle with Novel Pepducin(TM) GPCR Modulator Platform and Strengthens Senior Management Team